PharmaCyte Biotech (Formerly Known As Nuvilex)
1971 Old Cuthbert Road
Cherry Hill
New Jersey
08034
United States
Tel: 856-433-6088
Fax: 856-354-1077
Website: http://www.nuvilex.com/
Email: info@nuvilex.com
375 articles about PharmaCyte Biotech (Formerly Known As Nuvilex)
-
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
4/19/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material that comprises its pancreatic cancer clinical trial product candidate does not cause systemic toxicity.
-
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
4/13/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), today announced that PharmaCyte has decided to accelerate preparations for the start of its Phase 2b clinical trial in locally advanced, inoperable pancreatic (LAPC) using its CypCapsTM clinical trial product.
-
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
4/5/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the appointment of Dr. Matthias Löhr to PharmaCyte’s Board of Directors.
-
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
3/22/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has successfully completed a 24-month product stability study required by the U.S. Food and Drug Administration (FDA) for its clinical trial product candidate, CypCaps™
-
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
3/16/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the financial and operational results for its third quarter ended January 31, 2022.
-
PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration
2/22/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), today announced the results of an additional, more finely detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that is used in PharmaCyte’s pancreatic cancer product candidate known as CypCaps™.
-
PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA
2/14/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), today provided an update on PharmaCyte’s activities to lift the U.S. Food and Drug Administration’s (FDA) clinical hold on PharmaCyte’s treatment for locally advanced, inoperable pancreatic cancer (LAPC).
-
PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference
1/6/2022
PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference.
-
PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells
1/4/2022
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), today announced that the empty capsule material that makes up PharmaCyte’s CypCaps® pancreatic cancer product candidate is not toxic for the encapsulated cells inside the CypCaps.
-
PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study
12/28/2021
PharmaCyte Biotech, Inc. today announced that it has successfully completed a 36-month stability study of the cells from its Master Cell Bank (MCB).
-
PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights
12/15/2021
PharmaCyte Biotech, Inc. NASDAQ: PMCB), announced today the financial results for its second quarter ended October 31, 2021, and provided an overview of recent operational highlights (PharmaCyte’s Fiscal Year begins May 1 and ends April 30).
-
PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay
12/8/2021
PharmaCyte Biotech, Inc. announced today the results of an additional, more detailed, analysis of the integration site of the cytochrome P450 2B1 gene from the augmented HEK293 cell clone that PharmaCyte uses in its CypCap™ product.
-
PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study
11/30/2021
PharmaCyte Biotech, Inc. announced the commencement of a pivotal study to determine if the treatment PharmaCyte uses for locally advanced, inoperable pancreatic cancer—Cell-in-a-Box combined with the cancer killing prodrug ifosfamide—can also delay the rate of production and accumulation of malignant ascites.
-
PharmaCyte Biotech Announces Cell Encapsulation Technology Material Does Not Cause Skin Irritation
11/12/2021
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the empty capsule material that makes up its CypCaps™ pancreatic cancer product does not cause skin irritation.
-
PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA
9/27/2021
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced further results from a third test of biocompatibility of its CypCaps™ product candidate for pancreatic cancer.
-
PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests
9/21/2021
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the results of a second U.S. Food and Drug Administration (FDA)-required test of biocompatibility of its CypCaps™ product for pancreatic cancer, which showed that the empty capsule material is “non-hemolytic.”
-
PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA
9/16/2021
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the first test results of the biocompatibility studies of its CypCaps™ clinical trial product candidate.
-
PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
9/8/2021
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually September 13-15, 2021.
-
PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study
8/31/2021
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), announced today that its clinical trial product, CypCaps™, remains stable and active at 18 months after completing the 18-month timepoint of ongoing product stability testing required by the U.S. Food and Drug Administration (FDA).
-
PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital Raise
8/25/2021
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte or Company), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Company will expand its product pipeline to again include its diabetes program and its malignant ascites program.